Company / Cash & Equivalents
Xenon Pharmaceuticals Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$199.2M
FY2025
5-year range
$57.2M / $199.2M
FY2021-FY2025
Trend
+39.6%
vs FY2024
Sector context
#85 of 207
Health Care
What the data says
At $199M, Xenon Pharmaceuticals Inc.'s cash & equivalents ranks #85 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $17M in FY2017 to $199M in FY2025.
Based on SEC 10-K filings.
$199M in FY2025 with a 5-year CAGR of +34.6%.
Improved from $149M to $199M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +51.5%
- 5-Year CAGR
- +34.6%
- 10-Year CAGR
- -
Sector benchmark
#85 of 207 in Health CareTop 41% of 207This company $199.2M Sector average $669.5M
▼
-70.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +34.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 39.6% year-over-year.
- Ranks #85 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $199.2M | +39.6% |
| FY2024 | $142.7M | -4.0% |
| FY2023 | $148.6M | +159.7% |
| FY2022 | $57.2M | -67.4% |
| FY2021 | $175.7M | +290.3% |
| FY2020 | $45.0M | +81.8% |
| FY2019 | $24.8M | -63.5% |
| FY2018 | $67.8M | +296.3% |
| FY2017 | $17.1M | +0.0% |
| FY2016 | $17.1M | -70.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026